Literature DB >> 23727580

Tubulin polymerization promoting protein 1 (TPPP1) increases β-catenin expression through inhibition of HDAC6 activity in U2OS osteosarcoma cells.

Alice V Schofield1, Cristina Gamell, Ora Bernard.   

Abstract

The Rho-associated coiled-coil kinase (ROCK) family of proteins, including ROCK1 and ROCK2, are key regulators of actin and intermediate filament morphology. The newly discovered ROCK substrate Tubulin polymerization promoting protein 1 (TPPP1) promotes microtubule polymerization and inhibits the activity of Histone deacetylase 6 (HDAC6). The effect of TPPP1 on HDAC6 activity is inhibited by ROCK signaling. Moreover, it was recently demonstrated that ROCK activity increases the cellular expression of the oncogene β-catenin, which is a HDAC6 substrate. In this study, we investigated the interplay between ROCK-TPPP1-HDAC6 signaling and β-catenin expression. We demonstrate that β-catenin expression is increased with ROCK signaling activation and is reduced with increased TPPP1 expression in U2OS cells. Further investigation revealed that ROCK-mediated TPPP1 phosphorylation, which prevents its binding to HDAC6, negates TPPP1-mediated reduction in β-catenin expression. We also show that increased HDAC6 activity resulting from ROCK signaling activation reduced β-catenin acetylation at Lys-49, which was also accompanied by its decreased phosphorylation by Caesin kinase 1 (CK1) and Glycogen synthase kinase 3β (GSK3β), thus preventing its proteasomal degradation. Overall, our results suggest that ROCK regulates β-catenin stability in cells via preventing TPPP1-mediated inhibition of HDAC6 activity, to reduce its acetylation and degradation via phosphorylation by CK1 and GSK3β.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CK1; Deacetylation; GSK3β; HDAC6; Microtubule; Mitogen; Phosphorylation; ROCK; ROCK1; TPPP1; caesin kinase 1; glycogen synthase kinase 3β; histone deacetylase 6; rho-associated coiled-coil kinase; tubulin polymerization promoting protein 1; β-Catenin; β-TrCP; β-transducin repeat-containing protein

Mesh:

Substances:

Year:  2013        PMID: 23727580     DOI: 10.1016/j.bbrc.2013.05.076

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Therapeutic applications of histone deacetylase inhibitors in sarcoma.

Authors:  Fan Tang; Edwin Choy; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2017-07-06       Impact factor: 12.111

2.  LIMK1 nuclear translocation promotes hepatocellular carcinoma progression by increasing p-ERK nuclear shuttling and by activating c-Myc signalling upon EGF stimulation.

Authors:  Zhihua Pan; Chaoqun Liu; Yunfei Zhi; Zhiyue Xie; Ling Wu; Muhong Jiang; Yujie Zhang; Rui Zhou; Liang Zhao
Journal:  Oncogene       Date:  2021-03-08       Impact factor: 9.867

3.  Vangl2 participates in the primary ciliary assembly under low fluid shear stress in hUVECs.

Authors:  Xin Sheng; Shuanglin Gao; Yan Sheng; Xiadan Xie; Junhua Wang; Yan He
Journal:  Cell Tissue Res       Date:  2021-11-05       Impact factor: 5.249

Review 4.  HDAC6: A unique HDAC family member as a cancer target.

Authors:  Sumeet Kaur; Prerna Rajoria; Madhu Chopra
Journal:  Cell Oncol (Dordr)       Date:  2022-08-29       Impact factor: 7.051

5.  Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.

Authors:  Valentina Cirello; Valentina Vaira; Elisa Stellaria Grassi; Valeria Vezzoli; Dario Ricca; Carla Colombo; Silvano Bosari; Leonardo Vicentini; Luca Persani; Stefano Ferrero; Laura Fugazzola
Journal:  Oncotarget       Date:  2017-02-07

6.  HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1.

Authors:  Mandy Beyer; Annette Romanski; Al-Hassan M Mustafa; Miriam Pons; Iris Büchler; Anja Vogel; Andrea Pautz; Andreas Sellmer; Günter Schneider; Gesine Bug; Oliver H Krämer
Journal:  Cancers (Basel)       Date:  2019-09-26       Impact factor: 6.639

Review 7.  HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Authors:  Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich
Journal:  Cancers (Basel)       Date:  2020-01-29       Impact factor: 6.639

8.  Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma.

Authors:  Haydee M Torres; Ashley M VanCleave; Mykayla Vollmer; Dakota L Callahan; Austyn Smithback; Josephine M Conn; Tania Rodezno-Antunes; Zili Gao; Yuxia Cao; Yohannes Afeworki; Jianning Tao
Journal:  Cancers (Basel)       Date:  2021-08-20       Impact factor: 6.639

9.  SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.

Authors:  Elisa Stellaria Grassi; Valeria Vezzoli; Irene Negri; Árpád Lábadi; Laura Fugazzola; Giovanni Vitale; Luca Persani
Journal:  Oncotarget       Date:  2015-11-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.